Glimepiride blocks potassium channels on the β cells of pancreas. Thus releases insulin. In addition it also has an extra pancreatic activity. Besides releasing insulin, glimepiride by itself improves the sensitivity of the insulin receptor and thus improves blood glucose control. Glimepiride has certain valuable advantages over other sulphonylureas like; Glimeperide causes insulin release in the same phases as that of natural pattern of insulin release. Thus, there is no continuous release of insulin, hence there are very less chances of hypoglycemia. Unlike other sulphonylurea, glimeperide improves or contributes to overcome insulin resistance (extra pancreatic action). This improves insulin sensitivity.

Type-2 diabetes (NIDDM)

One tablet once daily.

The most common adverse effects noted were dizziness, headache, nausea.

Hypersensitivity to Glimepiride

GEPRIDE 1MG TABLET is available as a strip of 10 tablets

Glimepiride blocks potassium channels on the β cells of pancreas. Thus releases insulin. In addition it also has an extra pancreatic activity. Besides releasing insulin, glimepiride by itself improves the sensitivity of the insulin receptor and thus improves blood glucose control. Glimepiride has certain valuable advantages over other sulphonylureas like; Glimeperide causes insulin release in the same phases as that of natural pattern of insulin release. Thus, there is no continuous release of insulin, hence there are very less chances of hypoglycemia. Unlike other sulphonylurea, glimeperide improves or contributes to overcome insulin resistance (extra pancreatic action). This improves insulin sensitivity.

Type-2 diabetes (NIDDM)

One tablet once daily.

The most common adverse effects noted were dizziness, headache, nausea.

Hypersensitivity to Glimepiride

GEPRIDE 2MG TABLET is available as a strip of 10 tablets

Glimepiride stimulates insulin release from pancreatic beta cells. It increases the effect of insulin by enhancing sensitivity and efficacy of insulin. Metformin has the potential advantage of decreasing insulin resistance and can be used as first line therapy in combination with sulphonylurea. Studies have shown that addition of metformin to sulphonylurea treated patients with inadequate glycemic control is associated with improved glycemic control, lower post prandial insulin and triglyceride concentration and improved dyslipidemia. All of these changes to decrease risk of coronary heart diseases Metformin in this combination are in sustained release form. This eliminates multiple dosing pattern of metformin and can be given once daily.

Type 2 diabetes (NIDDM)

One tablet once a day

Common adverse effects include dizziness, asthenia (generalized weakness), headache, nausea and hypoglycemia.

GEPRIDE M1 TABLET is available as a strip of 10 tablets

Glimepiride stimulates insulin release from pancreatic beta cells. It increases the effect of insulin by enhancing sensitivity and efficacy of insulin. Metformin has the potential advantage of decreasing insulin resistance and can be used as first line therapy in combination with sulphonylurea. Studies have shown that addition of metformin to sulphonylurea treated patients with inadequate glycemic control is associated with improved glycemic control, lower post prandial insulin and triglyceride concentration and improved dyslipidemia. All of these changes to decrease risk of coronary heart diseases Metformin in this combination are in sustained release form. This eliminates multiple dosing pattern of metformin and can be given once daily.

Type 2 diabetes (NIDDM)

One tablet once a day

Common adverse effects include dizziness, asthenia (generalized weakness), headache, nausea and hypoglycemia.

GEPRIDE M2 TABLET is available as a strip of 10 tablets

Glimepiride stimulates insulin release from pancreatic beta cells. It increases the effect of insulin by enhancing sensitivity and efficacy of insulin. Metformin has the potential advantage of decreasing insulin resistance and can be used as first line therapy in combination with sulphonylurea. Studies have shown that addition of metformin to sulphonylurea treated patients with inadequate glycemic control is associated with improved glycemic control, lower post prandial insulin and triglyceride concentration and improved dyslipidemia. All of these changes to decrease risk of coronary heart diseases Metformin in this combination are in sustained release form. This eliminates multiple dosing pattern of metformin and can be given once daily.

Type 2 diabetes (NIDDM)

One tablet once a day

Common adverse effects include dizziness, asthenia (generalized weakness), headache, nausea and hypoglycemia.

GEPRIDE M3 TABLET is available as a strip of 10 tablets

Glucozid is the most beneficial oral antidiabetic agent belonging to the class of sulfonylureas. Glucozid achieves better glucose control, has lower incidence of secondary failure rates, lesser hypoglycemic events and potential free radical scavenging activity.

NIDDM when dietary modification has failed

Treatment is started with a dose of 40-80 mg/day just before meal o.d, increasing by 40 or 80 mg every few days if necessary to a max. of 320 mg. More than 160 mg is given as b.i.d dose. The treatment should begin with low doses in patients with renal and/or hepatic impairment.

Insulin dependent diabetes mellitus, Pregnancy, Severe renal insufficiency, Hepatic impairment, Thyroid impairment.

Hypoglycemia, headache, gastrointestinal upsets, nausea and dizziness has been reported and skin reactions, including rash, pruritis, erythema may occur.

Glucozid is available as a strip of 10 tablets.

This is a combination of two oral antidiabetic which works by two different mechanisms. Improves glycemic control in patients not adequately controlled with monotherapy, treats both the defects of diabetes mellitus i.e. deficiency of insulin secretion and increased insulin resistance.

Type-II diabetes

Lactic acidosis, nausea, vomiting, diarrhea, and lower abdominal pain are rarely seen.

Hypersensitivity, Impaired renal function, Liver damage

GEPRIDE M1 FORTE TABLET is available as a strip of 10 tablets

This is a combination of two oral antidiabetic which works by two different mechanisms. Improves glycemic control in patients not adequately controlled with monotherapy, treats both the defects of diabetes mellitus i.e. deficiency of insulin secretion and increased insulin resistance.

Type-II diabetes

Lactic acidosis, nausea, vomiting, diarrhea, and lower abdominal pain are rarely seen.

Hypersensitivity, Impaired renal function, Liver damage

GEPRIDE M2 FORTE TABLET is available as a strip of 10 tablets